Avidity and Affiliates Report Shared Voting Power over 9.9% of CNTX
Rhea-AI Filing Summary
Avidity Partners and affiliated funds filed a Schedule 13G reporting significant passive holdings in Context Therapeutics Inc. The filing discloses that certain Avidity reporting persons hold shared voting and shared dispositive power over 9,126,176 shares, representing approximately 9.9% of the outstanding common stock. Individual fund positions reported in the filing include Avidity Master Fund LP with 5,183,700 shares (5.6%) and Avidity Private Master Fund I LP with 7,776,296 shares (8.4%). Michael Gregory is listed among the reporting persons with the same shared power totaling 9,126,176 shares.
The filing indicates no sole voting or dispositive power for any reporting person and includes a certification that the securities were not acquired to change or influence control of the issuer. Exhibits referenced in the filing include a Joint Filing Agreement and Control Person Identification.
Positive
- Reported beneficial ownership of 9,126,176 shares representing 9.9% of Context Therapeutics common stock.
- Detailed fund-level positions disclosed, including 5,183,700 shares (5.6%) for Avidity Master Fund LP and 7,776,296 shares (8.4%) for Avidity Private Master Fund I LP.
- Filed Schedule 13G with a certification of passive intent and included exhibits (Joint Filing Agreement and Control Person Identification) as part of the disclosure.
Negative
- None.
Insights
TL;DR: Avidity reports a material passive stake of 9.9% in CNTX with shared voting/dispositive power; this is a notable ownership disclosure for investors.
The Schedule 13G shows Avidity-affiliated entities collectively holding 9,126,176 shares (9.9%) of Context Therapeutics common stock and reporting only shared voting and dispositive powers. The filing is a passive disclosure rather than an active 13D claim, and it includes a formal certification that the holdings were not acquired to influence control. For investors, the key facts are the size of the position and the coordinated reporting across multiple Avidity entities, both explicitly stated in the filing.
TL;DR: Coordinated Avidity ownership is disclosed as passive (Schedule 13G) with shared powers; governance impact is limited absent additional actions.
The filing documents shared voting and dispositive power across several Avidity entities rather than any sole control. Reported fund-level holdings include 5,183,700 shares (5.6%) for Avidity Master Fund LP and 7,776,296 shares (8.4%) for Avidity Private Master Fund I LP, with aggregate shared power of 9,126,176 shares (9.9%). The report includes a certification stating the securities were not acquired to change or influence control and attaches a Joint Filing Agreement and Control Person Identification exhibit, all as stated in the document.
FAQ
How many shares of CNTX does Avidity beneficially own?
What percentage of CNTX common stock does Avidity report owning?
Do any reporting persons have sole voting or dispositive power over the shares?
Which Avidity funds are specifically identified and what are their reported holdings?
Does the filing state intent to influence control of Context Therapeutics (CNTX)?